Positive Dupixent® (dupilumab) Phase 3 Data in Children

Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet

Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Japan , Paris , France General , France , Regeneron , Walterj Hamlin , Regeneron Velocimmune Technologyregeneron , Georged Yancopoulos , Amys Paller , Prnewswire Regeneron Pharmaceuticals Inc , Regeneron Pharmaceuticals Inc , Twitter , Regeneron Genetics Center , Drug Administration , Nasdaq , Northwestern University Feinberg School Of Medicine , Teva Pharmaceutical Industries Ltd , Exchange Commission , European Union , European Medicines Agency , Dupilumab Development Programdupilumab , Euronext , European Medicines , Northwestern University Feinberg School , Atopic Dermatitisatopic , Dupixent Trialthe Phase , Global Assessment , Eczema Area , Severity Index , Patient Oriented Eczema Measure , Atopic Dermatitis , Dermatology Life Quality Index , Infant Dermatitis Quality , Life Index , Dermatitis Family Impact , Velocimmune Technologyregeneron , Chief Scientific Officer George , Development Programdupilumab , Prescribing Informationincluding Patient , Forward Looking Statements , Digital Mediathis , Regeneron Pharmaceuticals , Product Candidates , Teva Pharmaceutical Industries ,